Surface Oncology (SURF) said Wednesday it appointed Denice Torres as chair of the board of directors. Torres has been a board member of the company since...
Surface Oncology (SURF) said Wednesday the US Food and Drug Administration has cleared the company's investigational new drug application for its...
...
Surface Oncology (SURF) on Monday announced plans to start a randomized Phase 2 clinical study evaluating its SRF388 potential antibody against IL-27 in...
| Address | 50 Hampshire Street Cambridge, Massachusetts 02139 |
| Phone | +1.617.714.4096 |
| Number of Employees | 76 |
| Recent SEC Filing | 01/14/2022 4 |
| President, Chief Executive Officer & Director | Robert W. Ross |
| Chief Financial Officer | Jessica Fees |
| Chief Scientific Officer | Vito J. Palombella |
| Chief Medical Officer | Alison M. O'Neill |
| Price Open | $3.98 |
| Previous Close | $3.93 |
| 52 Week Range | $3.71 - 13.90 |
| Market Capitalization | $171.6 M |
| Shares Outstanding | 46.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/08/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 12.00 |
| Earnings per Share | $0.31 |
| Beta vs. S&P 500 | N/A |
| Revenue | $59.4 M |
| Net Profit Margin | 14.33% |
| Return on Equity | 8.69% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
